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Grafts of normal and neoplastic hemopoietic cells fail or grow poorly in certain 
lethally irradiated allogeneic mice, including F1 hybrid recipients of parental cells 
(1-4).  The manifestation  of histoincompatibility in the latter host/donor  com- 
bination has been referred to as hybrid resistance, an apparent contradiction to 
the classic laws of transplantation.  A similar resistance to allogeneic bone marrow 
cell (BMC) 1 grafts has been shown to occur in other mammalian  species (5-7), 
and may contribute to clinical marrow graft failure in humans (8). The resistance 
is effected by an unusual  host-vs.-graft reaction that is radioresistant  and  inde- 
pendent of the thymus (9-19). The sharing of numerous characteristics between 
this  resistance  and  natural  cytotoxic activity in  vitro against  a  broad range  of 
target cells suggests that  the natural  resistance to hemopoietic cells is mediated 
by a subset of natural killer (NK) cells (13-15). Treatment of mice with antisera 
with selective reactivity against NK cells indeed abrogates hemopoietic resistance 
as well (16, 17). To date, however, the growing list of properties shared between 
such resistance and  NK cell activity does not include the single most pertinent 
property of hemopoietic resistance, i.e., its immunogenetic specificity. 
Hybrid resistance in mice is controlled by the hemopoietic histocompatibility 
(Hh)  loci,  most  of which  are  linked  to  the  major  histocompatibility  complex 
(MHC) of the mouse, the H-2 (reviewed in  18).  One of the best known Hh loci, 
Hh-1, is tightly linked to the H-2D region.  It has been hypothesized that these 
genes are noncodominantly expressed so that donor cells homozygous for a given 
allele of an  Hh  locus are recognized as nonself and are  rejected by F~  hybrid 
recipients  heterozygous  for  the  same  allele  (9).  In  spite  of  its  unorthodox 
assumption of noncodominant,  or co)recessive, inheritance of Hh genes (19), the 
hypothesis  successfully  explains  the  genetic  constraints  of  both  hybrid  and 
allogeneic  resistance  (18).  Direct  evidence  is  still  lacking,  however,  for  the 
existence  of effector cells capable  of specifically recognizing  the  putative  Hh 
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antigens, thereby mediating parental marrow graft rejection. In fact, some recent 
observations  (20-22,  23)  tend  to  support  an  alternative  hypothesis  that  the 
genetic  specificity  of hemopoietic  resistance  rests  on  regulatory  mechanisms 
rather  than  on  the  postulated  recognition  specificity of effector cells.  These 
observations include the findings that bone marrow cells from normal mice or 
healthy humans are susceptible to NK cell-mediated cytolysis in vitro (20-22), 
and that resistance to bone marrow allografts can be reconstituted by an NK- 
like cell  line (23).  Moreover,  the  level of NK activity is in  part  controlled by 
genes linked to the MHC (24-28). 
Thus,  definitive information on  the  recognition  specificity of the  effectors 
mediating hybrid resistance is a  prerequisite  for the further understanding of 
this and other  natural  resistance phenomena.  To directly test the recognition 
specificity  of the  effectors,  an  in  vivo  competitive  inhibition  assay  has  been 
developed. The experiments described in this initial report used a panel of tumor 
cells as inhibitors, several of which were chosen on the basis of susceptibility to 
cytolysis by NK cells in vitro. The results provide the first direct evidence for 
the existence of radioresistant effectors that specifically recognize cellular deter- 
minants  controlled  by  gene(s)  within,  or  closely  linked  to,  the  H-2D  region. 
These  effectors are  reactive only with the  H-2D  homozygous tumor cells,  an 
indication of Hh-1 restriction of recognition. 
Materials and Methods 
Animals.  Female C57BL/6N (B6), C57BL/10ScSn (BI0), C3H/HeN (C3H),  DBA/ 
2, (C57BL/6 ×  DBA/2)F1 (B6D2F~), and B10.A mice were obtained from the Animal 
Genetics and Production Branch, Division of Cancer Treatment, National Cancer Insti- 
tute. Female (C57BL/10 x  C3H)F~  (B10C3F~) mice used were obtained from Health 
Research Inc., West Seneca, NY.  All other strains of mice used were bred in our own 
colony, including B10.D2, BIO.A(2R), B10.A(4R), B10.A(5R), [B10.A ×  B10.A(2R)]F~, 
and (BALB.B10 ×  BALB/c)F~. Bone marrow donors were 5-8  wk old and recipients 
were 12-20 wk old. 
Tumor cells.  The following cell lines were maintained in vivo as ascitic tumors by serial 
passage in syngeneic mice: benzpyrene-induced lymphoma EL-4 (H-2 b, C57BL/6), radia- 
b  tion-induced lymphoma L5  M F-22 [H-2  , B 10.129(5 M)], methylcholanthrene-induced  leu- 
d  k  kemia L 1210 (H-2  , DBA/2), lymphosarcoma GL-1 (H-2  , C3H), erythroleukemia HFLb/ 
d [H-2 b/a, (BALB.B10 ×  BALB/c)FI] (29), and Friend virus-induced myeloid leukemia 
427E (H-2 b/d, B6D2FI) (30). The following  radiation-induced lymphomas  were maintained 
by serial passage in syngeneic mice as splenic tumors: LAF-17 (H-2 a, B10.A),  RDNM-27 
(H-2 a, B10.D2), LHM-14 [H-2 h~, B10.A(2R)],  L4RM-73 [H-2 h4, B10.A(4R)],  LIM-65 [H- 
2  i5,  B10.A(5R)],  and  LBA ×  2RM-80  (H-2 a/h2, [B10.A  ×  B10.A(2R)]F1).  The Friend 
virus-transformed bone marrow stem cell line 416B (H-2 b/a, B6D2FI) (31), Moloney virus- 
induced lymphoma YAC-1 (H-2 a, A/Sn), Rauscher virus-induced iymphoma RBL-5 (H- 
2  b, B6), radiation-induced leukemia RL~-I (H-2 a, BALB/c), and a subline of EL-4 (not 
an interleukin 2  [IL-2]  secreter) were maintained in vitro. The cell  line HFLb/d was 
originally a gift from Dr. T. V. Rajan. Both the 427E and 416B lines were a gift of Dr. 
S. K. Ruscetti. 
Irradiation.  Recipient mice were exposed to 800-950  rad of a37Cs gamma radiation 
from a Gammacell 20 Small Animal Irradiator (Atomic Energy of Canada, Ltd., Ottawa, 
Canada) at a dose rate of 95 rad/min, 2-3 h before the intravenous injection of either 
tumor or normal BMC. Tumor cells to be used as inhibitors were suspended in ice-cold 
Hanks' balanced salt solution (HBSS) and exposed to I 0,000 rad of ~37Cs gamma radiation 
using an Isomedix irradiator (model M-38-2; Isomedix Inc., Parsippany, NJ) at the dose 1 134  H-2/Hh-RESTRICTED EFFECTORS OF  NATURAL  RESISTANCE 
rate of 1,000 rad/min.  Irradiated tumor cells were injected into mice within 30 min of 
irradiation. 
Treatment with Polyinosinic:Polycytidylic  Acid (p-I:C).  Lyophilized p-I:C (Sigma Chemical 
Co., St. Louis, MO) was dissolved in HBSS at a concentration of 1 mg/ml. Both lyophilized 
and dissolved p-I:C were stored at -20°C. Mice were in'ectedLj  p  yintra  eritoneali  with 100 
/zg  of p-I:C  18  h  before  injection  with  BMC  or  [125I]5-iodo-2'-deoxyuridine ([l~5I]- 
IUdR)-labeled tumor cells (see below). 
Splenic [125I]IUdR Uptake Assay for Marrow Cell Proliferation.  The standard assay  for 
proliferation of grafted hemopoietic cells in lethally irradiated recipients has been previ- 
ously described (32, 33). The assay was modified, as required, to include an intravenous 
injection(s) of irradiated  tumor  cells.  Briefly,  lethally  irradiated  recipient  mice  were 
injected intravenously with inhibitor cells suspended in  1.0 ml of HBSS 3 h before the 
intravenous injection of BMC,  unless  otherwise stated;  in  some experiments the  time 
interval between tumor and  BMC injections was the variable to be tested.  Viable cell 
counts were  made  with  a  hemocytometer, based  on  trypan  blue  dye exclusion.  The 
proliferation of donor  cells  in  the  spleens  of recipients  was  assessed  5-7  d  later  by 
measuring the incorporation of [~sI]IUdR. 30 min before the intraperitoneal injection of 
0.25 #Ci [~sI]IUdR (Amersham Corp., Arlington Heights, IL), each animal was injected 
with 10  -7 mol i.p. of 5-fluoro-2'-deoxyuridine (FUdR) to reduce competition by endoge- 
nous thymidylate. All animals were sacrificed 18 h after isotope injection and their spleens 
removed and placed in glass counting vials.  [l~sI]IUdR retention was measured with a 
well-type gamma scintillation counter. The retention of [~sI]IUdR  in the spleens was 
expressed as  a  percentage  of the  injected  isotope dose  (%  injected dose).  Irradiated 
syngeneic recipients served to measure the full growth potential of the grafted BMC. The 
spleens of lethally irradiated  mice not  injected with  BMC  or injected with  irradiated 
tumor cells alone retained 0.01-0.03% of the injected isotope. 
In Vitro [125I]IUdR Labeling of Tumor Cells  for Localization Studies.  Tumor cells to be 
labeled were suspended at the concentration of 106/ml in RPMI  1640 medium supple- 
mented with 10% fetal calf serum and antibiotics. FUdR (2 x  10  -s mol) was added to 50 
ml of cell suspension in each plastic petri dish and incubated for 20 min at 37°C in a 5% 
COs incubator.  15 #Ci of [~sI]IUdR was then added to each culture dish and the cells 
were incubated for an additional 18 h. The cells were harvested and washed extensively 
with HBSS. They were resuspended in HBSS at a concentration of 106/ml and injected 
intravenously into  lethally irradiated  recipients.  At  selected times after injection,  the 
animals were sacrificed, their spleens removed, and the amount of retained a~sI activity 
in each spleen determined as described above. 
Statistical Analysis.  The  data  are  expressed as  geometric means  of the  percent  of 
injected  [~25I]IUclR dose.  Group  comparisons  were  made  using  Student's  t  test  for 
geometric means.  Differences between groups were considered significant when P  was 
_<0.05. 
Results 
Inhibition of Hybrid Resistance  to Parental Bone Marrow Grafts by Irradiated Lym- 
phoma Cells.  Two examples of hybrid resistance are shown in Fig. 1. The growth 
of parental B6 (H-2  b) BMC in irradiated B6D2Fl (H-2  b/d) recipients was impaired 
as compared with that of the same cells grafted into irradiated syngeneic hosts 
(Fig.  1 A). In this FI hybrid recipient vs. parental donor combination, growth of 
parental BMC was completely suppressed when graft size was below  1-2 x  106. 
When  the  graft  size  was  increased,  proportionally  more  BMC  escaped  from 
rejection and proliferated in the F1 host spleen. Similarly, grafts of parental B 10 
(H-2  b)  BMC  were  resisted  by  irradiated  B10C3F1  (H-2  b/k)  hosts  (Fig.  1B). 
However,  resistance  by  B10C3F1  mice  was  somewhat  weaker  than  that  by 
B6D2F1 mice, as judged by the partial escape from rejection of 2 ×  106 or larger DALEY  AND  NAKAMURA  1135 
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FmORE  1.  Inhibition of hybrid resistance against parental H-2  b BMC grafts by irradiated H- 
2 b lymphoma cells. (A) Graded numbers of B6 BMC were injected into irradiated B6D2F, (A, 
A) or B6 (O, O) mice, either without additional treatment (A, O) or after inoculation of 5 X 
107 irradiated EL-4 cells 3 h earlier (&, O). Graded numbers of B6D2FI BMC were injected 
into irradiated B6D2FI mice otherwise untreated ([]) or after inoculation of 5 X 107 irradiated 
EL-4 cells 3 h earlier (1). [t25I]IUdR uptake in the recipient spleens was tested 5 d  later. (B) 
Graded numbers of BI0 BMC were injected into irradiated BIOC3FI (A, &)7 or B10 (O, O) 
mice, either without additional treatment (A, O) or after inoculation of 5 X I0  L5MF-22 cells 
3 h  earlier (&, 0).  [l~5I]IUdR uptake by the recipient spleens was measured 5 d  later. Each 
point represents the mean of three to six mice. 
grafts in B10C3Ft  hosts. In B6D2Ft mice, a comparable degree of escape from 
rejection occurred only with 5 ×  108 or larger grafts. 
To test the ability of H-2 b lymphoma cells to inhibit resistance to parental H- 
2 b BMC, EL-4 cells of B6 origin or L5MF-22 cells of B10.129(5M) origin were 
exposed to  10,000 rad of 3' irradiation and injected at a dose of 5  ×  107 cells/ 
mouse into irradiated B6D2FI or B10C3Fx mice, respectively, 3 h before trans- 
plantation of graded numbers of parental  BMC.  Partial  (Fig.  1 A) or complete 
(Fig. 1 B) inhibition of hybrid resistance by irradiated lymphoma cells ensued, as 
indicated by higher levels of splenic [125I]IUdR uptake 5 d later in the lymphoma- 
injected  hosts as  compared with  the  hosts grafted  with  BMC  alone.  Residual 
DNA synthesis by irradiated lymphoma cells, if any at all, did not contribute to 
the increase in [125I]IUdR uptake for the following reasons. First, irradiated mice 
injected with these lymphoma cells but not BMC failed to incorporate [125I]IUdR 
above  the  levels  of  incorporation  (0.01-0.03%  splenic  uptake)  in  irradiated 
control mice not grafted with cells (data not shown). Second, aliquots of the same 
irradiated lymphoma cells had no effect on [125I]IUdR uptake by irradiated hosts 
given syngeneic BMC grafts (Fig.  1, A and B).  The relative effectiveness of the 
inhibition of rejection, as measured by the increase in [12~I]IUdR uptake, was 
greatest  for the BMC dose at the inflection point of resistance.  The data also 
indicate a  higher inhibition efficiency by the same number of lymphoma cells 
against the weaker resistance of B 10C3FI than that of B6D2F1 mice. Fifty million 
inhibitor cells allowed  the  growth  of B6  BMC  in  B6D2Ft  mice to an  extent 
substantially below that in syngeneic B6 hosts (Fig.  1A), but the growth of B10 1136  H-2/Hh-RESTRICTED  EFFECTORS  OF  NATURAL  RESISTANCE 
BMC in  B10C3F~  was raised by the  same number  of inhibitor  cells to a  level 
comparable to that in syngeneic B 10 hosts (Fig.  1 B). The two H-2  b lymphomas 
EL-4  and  L5MF-22  were  indistinguishable  in  their  inhibitory  capacity  when 
simultaneously tested in the same F~ recipient/parental BMC donor combinations 
(data not shown).  Irradiated  EL-4 cells from the  same pool were also injected 
into irradiated  B6 and B6D2FI recipients of syngeneic BMC grafts. The effect 
of EL-4 cells on syngeneic BMC growth, if any, was a slight, statistically insignif- 
icant depression  rather  than  an enhancement  of growth.  Presumably, this  was 
due to a nonspecific crowding effect, since the injection of unrelated lymphoma 
cells  resulted  in  a  similar  degree  of depression  (data  not  shown),  Similarly, 
injection of L5MF-22 cells had no effect on the growth of B 10 BMC in syngeneic 
hosts. 
Dependence of Inhibition on the Number of Irradiated Lymphoma Cells and the Time 
of their Injection.  Lethally irradiated B6D2FI mice were inoculated with graded 
numbers of irradiated  EL-4 cells 3 h before the injection of either 5 x  105, 2 x 
10 6,  or  7 X  106 B6 BMC. B6D2F1 recipients given only the B6 BMC served as 
controls. The three doses of B6 BMC were chosen to cover the three identifiable 
levels of resistance indicated by the data in Fig. 1 A, i.e., complete suppression of 
the growth of 5 x  10  ~ parental  BMC, the inflection point at 2 X  106 cells, and 
the partial  escape of 7  x  106 B6 BMC from rejection. The inhibition  of BMC 
rejection by EL-4 cells was dependent on both the BMC dose and the EL-4 cell 
dose (Fig. 2). With 2 x  106 or 7 x  106 B6 BMC, inhibition was a linear function 
of the  EL-4  cell  dose.  However,  with  5  X  105  BMC,  substantial  inhibition 
occurred only when 5 x  107 or higher numbers of EL-4 cells were injected, an 
indication  that  irradiated  EL-4  cells  compete  with  B6  BMC  as  targets  for 
rejection. If this interpretation is correct, it is expected that the time of inhibitor 
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FIGURE 2.  Dependence of the inhibition of hybrid resistance on both the bone marrow graft 
size and  the  inhibitor cell dose.  Parental  B6  BMC  were  injected into irradiated B6  (open 
symbols) or B6D2F1 (closed symbols) mice at the dose of 5 x  l0  s (["1, II), 2 X  10  6 (O, 0), or 7 
x  10  6 (A, &) cells.  Fl  mice receiving B6  BMC were  either not treated otherwise or given 
graded numbers of irradiated EL-4 cells 3 h  before B6 BMC transplantation. All mice were 
tested for splenic [t2Sl]IUdR uptake 5 d  later. Each point represents the mean of four to six 
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TABLE  I 
Temporal Requirement for Inhibition, by Irradiated EL-4 Cells, of the Resistance of B6D2Fx Mice 
Against Parental B6 Bone Marrow Grafts 
Recipient* 
Group  (n) 
EL-4*  Mean percent [n2sI]IUdR  uptake 
-24 h  -3 h  +24 h  (95% confidence limits) 
1  B6  (4)  -  -  -  2.3019 q 
2  B6D2Fn  (5)  -  -  -  0.1254 q 
3  B6D2Fn (4)  +  -  -  0.0773 q 
4  B6D2F1  (6)  -  +  -  0.3555 q 
5  B6D2FI  (6)  -  -  +  0.1382 q 
6  B6D2Ft (5)  +  +  -  0.8787, 
7  B6D2Fn  (5)  -  +  +  0.4788 q 
8  B6D2Fn  (4)  +  +  +  1.1333, 
1.5878-3.3372) 
0.0865-0.1817) 
0.0419-0.1426) 
0.1447-0.8735) 0 
0.0854-0.2238) 
0.5416-1.4255) 0 
0.2546-0.9001) ! 
0.7059-1.8195) 0 
* Irradiated recipients received 5 X 108 B6 BMC at 0 h. 
* Each inoculum consisted of l0 T irradiated cells per recipient. 
0 Statistically significant (P <  0.05) inhibition of graft rejection as compared to group 2. 
TABLE  II 
Specificity of lnhibition of Hybrid Resistance by Tumor Cells 
Recipient*  Inhibitor*  Mean percent [12sI]IUdR uptake 
Exp.  (n)  Tumor line  H-2  (95% confidence limits) 
B6 
B6D2F 
B6D2F 
B6D2F 
B6D2F 
B6D2F 
B6D2F 
B6D2F 
(5)  --  --  2.2422 (1.0576-4.7538) 
(6)  --  --  0.3153 (0.1752-0.5677) 
(6)  EL-4 (in vivo)  b  0.8872 (0.6316-1.2465) ! 
(5)  L1210  d  0.1907 (0.1214-0.2995) 
(6)  GL-1  k  0.0625 (0.0196-0.1993) 
(6)  416B  b/d  0.2408 (0.1142-0.5077) 
(5)  427E  b/d  0.1032 (0.0332-0.3208) 
(6)  HFL b/d  b/d  0.1709 (0.0665-0.4395) 
B6  (5)  --  --  2.7621  (1.9257-3.9617) 
B6D2F~  (5)  --  --  0.6071  (0.3996-0.9224) 
B6D2F~  (6)  EL-4 (in vitro)  b  1.6490 (1.1576-2.3490) 0 
B6D2F~  (5)  RBL-5  b  1.3202 (0.9324-1.8692) 0 
B6D2F,  (4)  RL~-I  d  0.7799 (0.5757-1.0566) 
B6D2F~  (6)  YAC-1  a  0.7400 (0.3734-1.4666) 
III  B10  (3)  --  --  1.3752 (0.6248-3.0270) 
BIOC3F, (5)  --  --  0.0468 (0.0264-0.0828) 
B10C3FI (4)  L5MF-22  b  0.5455 (0.3846-0.7736) 0 
B10C3F,  (5)  GL-1  k  0.0458 (0.0207-0.1016) 
B10C3F,  (6)  YAC-I  a  0.0778 (0.0341-0.1779) 
* Irradiated recipients received either 5 ×  106 B6 BMC (Exps. I & II) or 106 BI0 BMC (Exp. III). 
* In all experiments, 5 ×  l0 T irradiated tumor cells were given to recipients 3 h before BMC grafts. 
| Statistically significant (P <  0.05) inhibition of graft rejection. 
cell injection relative to BMC  grafting should critically influence the effectiveness 
of inhibition.  To  test this, 5  ×  106 B6 BMC  were injected into irradiated  B6D2FI 
mice  and  107  irradiated  EL-4  cells  were  injected  once,  twice,  or  three  times 
within 24  h  before  or after  BMC  grafting.  The  relatively low dose of EL-4 cells 
was selected to facilitate comparisons  among  the different  experimental  groups. 1138  H-2/Hh-RESTRICTED  EFFECTORS  OF  NATURAL  RESISTANCE 
The results are summarized in Table I. A single dose of EL-4 cells was effective 
only when it was given 3 h before BMC transplantation (cf., groups 3, 4, and 5). 
When mice were given EL-4 cells 3 h  before BMC grafting, an additional dose 
24 h before BMC grafting augmented inhibition but one 24 h after BMC injection 
did so only slightly (cf., groups 6 and 7 with group 4). The regime of three doses 
of inhibitor cells was the most effective, but relatively little was gained over the 
two doses at -24 and -3 h (cf., groups 6 and 8). These data suggest that EL-4 
cells  must  be  present  in  the  spleen  simultaneously with  the  target  BMC  for 
inhibition to take place, and that the critical phase of BMC rejection is complete 
within 24  h  of grafting.  Additional data presented later (Fig.  3) lend further 
support to these conclusions. 
Specificity of Inhibition  of Hybrid Resistance by Irradiated Tumor Cells.  The kinetic 
data presented thus far strongly suggest that the inhibition of hybrid resistance 
by H-2  b lymphoma cells is due to the competitive inhibition of resistance at the 
level of target cell recognition by the effector cells mediating this resistance. To 
substantiate this interpretation and to analyze the recognition specificity of the 
effectors, lymphoma and  other tumor cells of standard  H-2  haplotypes were 
tested for their inhibitory capacity. Among the tumor cell lines tested were NK- 
susceptible YAC-1, RBL-5, and RLd-1, and three H-2 heterozygous lines. One 
of the  latter,  416B,  is  highly  susceptible  to  NK-mediated  cytolysis  in  vitro 
(unpublished observation).  As shown in Table  II, cells of the H-2  d (L1210  of 
DBA/2,  RLd-1  of BALB/c), H-2  a (YAC-1  of A/Sn), and H-2  k (GL-1  of C3H) 
haplotypes were unable to inhibit the resistance of B6D2FI mice to parental B6 
BMC, but another H-2  b lymphoma, RBL-5 (B6 origin), was nearly as inhibitory 
as EL-4 cells. Since the NK-susceptible lymphoma cells were maintained by in 
vitro passage, an in vitro subline of EL-4 was used in experiment II. The H-2  b/d 
heterozygous "stem cell" line 416B and myeloid leukemia 427E of B6D2F~  bone 
marrow origin were noninhibitory, as were erythroleukemic cells HFLb/d  of 
(BALB.B 10 × BALB/c)F1 origin. These data indicate that the inhibitory capacity 
of tumor cells is associated with  the H-2  b haplotype, that the H-2  b haplotype 
must be in the homozygous state to be inhibitory, and that susceptibility to NK- 
mediated cytolysis in vitro is irrelevant for inhibitory capacity in vivo. 
In the next series of experiments, B10C3F~  mice were grafted with parental 
B 10 BMC and tested for inhibition of resistance by radiation-induced iymphoma 
cells from congenic strains of mice with informative H-2 haplotypes. Since the 
lymphoma lines used were splenic rather than ascitic, the L5MF-22 cells used as 
the positive control for inhibition  were from the splenic line from which the 
ascitic subline used in earlier experiments was derived. Growth characteristics of 
the splenic lymphomas were comparable.  The  results  of three representative 
experiments are shown in Table III. Though the efficiency of inhibition by these 
splenic tumors was lower than that by ascitic tumors, the presence or absence of 
inhibitory activity was always clearly demonstrable. The H-2  a (LAF-17 of B ! 0.A) 
and H-2  d (RDNM-27 of B10.D2) cells were ineffective as inhibitors. Cells with a 
recombinant haplotype carrying the b allele in the D  region only [LHM-14 of 
B10.A(2R)] or in the D end regions [L4RM-73 of B10.A(4R)] were inhibitory, 
but those cells carrying the b  allele in the K end only [LIM-65 of B10.A(5R)] 
were noninhibitory. LBA ×  2RM-80  lymphoma cells that were derived from a DALEY AND  NAKAMURA  1139 
TABLE  III 
Mapping of Gene(s) Controlling Inhibitory Activity of Lymphomas 
Exp. 
Inhibitor*  Mean percent [l~SI]IUdR up- 
Recipient* 
H-2  take 
(n)  Tumor line  (KAESD)  (95% confidence limits) 
B10  (5)  --  --  1.6633 (1.3068-2.1169) 
BIOC3Ft (4)  --  --  0.0747 (0.0357-0.1563) 
B10C3F~ (5)  L5MF-22  bbbbb  0.5534 (0.3913-0.7827) 0 
B10C3F~ (5)  LAF-17  kkkdd  0.0638 (0.0360-0.1129) 
kkkdd 
BIOC3FI (5)  LBA x 2RM-80  kkkdb  0.0408 (0.0238-0.0698) 
II  BIOC3F~ (6)  --  --  0.0606 (0.0450-0.0815) 
B10C3F~ (7)  L4RM-73  kkbbb  0.2349 (0.1629-0.3386) 0 
B10C3F~ (5)  RDNM-27  ddddd  0.0700 (0.0371-0.1320) 
B10C3FI (3)  LIM-65  bbkdd  0.0444 (0.0209-0.0945) 
III  BI0  (4)  --  --  2.5682 (1.5829-4.1666) 
B10C3F~ (5)  --  --  0.2603 (0.1777-0.3814) 
B10C3F~ (8)  LHM-14  kkkdb  0.6724 (0.3629-1.2457) I 
B10C3FI (6)  LAF-17  kkkdd  0.2950 (0.1606-0.5420) 
BIOC3F~ (6)  LIM-65  bbkdd  0.1408 (0.0688-0.2881) 
* Irradiated recipients received either 106 (Exp. I) or 1.5 × 106 (Exps. II & III) B10 BMC. Splenic 
[I~5I]IUdR uptake was tested on day 5 (Exp. I), day 6 (Exp. II), or day 7 (Exp. III). 
7  8  * Either 5 × 10  (Exp.  I) or 10  (Exps. II & III) irradiated tumor cells were given 3 h before BMC 
grafts. 
! Statistically  significant (P < 0.05) inhibition of graft rejection. 
[B 10.A X B 10.A(2R)]F1 mouse were not inhibitory. Thus, the inhibitory capacity 
of tumor cells is dependent on the homozygosity of a gene or genes within or on 
the telomeric side of the H-2D region. 
Effect of the Interferon  Inducer Polyd:C on Hybrid Resistance and the Spec~city of 
Inhibition.  Since interferon (IFN)  is known  to have an antiproliferative effect 
on hemopoietic bone marrow-derived cells (34), the effect of a  single injection 
of p-I:C 18 h before BMC grafting was tested in syngeneic transplantation (Table 
IV,  Exps.  I  and  II).  Although  the  growth  of syngeneic BMC  in  p-I:C-treated 
recipients had a  tendency to be slightly less than that in untreated recipients, a 
statistically  significance  difference was  not  observed  under  the  experimental 
conditions in the strains of mice used.  In contrast, growth of parental BMC was 
markedly reduced in p-I:C-treated F1 hosts as compared with untreated F~ hosts, 
indicating an amplification of resistance by p-I:C  treatment  (Exp.  III).  At  this 
dose of parental BMC (5 ×  106), the resistance in untreated recipients was partial 
and, hence, amenable to augmentation. Since p-I:C or IFN augments the cytolytic 
activity (35-37) and the target-binding capacity of NK cells for some targets (38), 
the specificity as well as the extent of inhibition of hybrid resistance by various 
tumor  cells  was  tested.  The  specificity of inhibition  was  unaltered  by  p-I:C 
treatment of recipients, including the inability of NK-susceptible YAC-1  cells to 
inhibit parental BMC graft rejection (Exp. III). The extent of the inhibition by 
EL-4 cells was reduced, presumably because the inhibition is a  function of the 
strength of resistance (Fig.  1). 1140  H-2/Hh-RESTRICTED EFFECTORS  OF  NATURAL RESISTANCE 
TABLE  IV 
Effect of the Interferon Inducer  pd:C on Hybrid Resistance and the Effector Specificity 
BMC  Mean percent [n~5IllUdR up- 
Recipient  Inhibi-  p-I:C*  take 
Dose  tor*  Exp.  (n)  Donor  (X 10  -6)  (95% confidence limits) 
II 
III 
B6  (4)  B6  4.0  -  -  1.9501 (1.3350-2.8488) 
B6  (3)  B6  4.0  -  +  1.6650 (1.1685-2.3726) 
B6  (4)  B6  8.0  -  -  3.0558 (2.4151-3.8666) 
B6  (3)  B6  8.0  -  +  2.9389 (2.6758-3.2279) 
B6D2Fn (3)  B6D2FI  2.0  -  -  1.1251 (0.5366-2.3589) 
B6D2Fx (3)  B6D2F1  2.0  -  +  0.9555 (0.3964-2.3037) 
B6D2F~ (4)  B6D2F~  8.0  -  -  1.9578 (1.7153-2.2346) 
B6D2F~ (4)  B6D2F~  8.0  -  +  2.0248 (1.6647-2.4629) 
B6  (6) 
B6D2Fn (6) 
B6D2F  (5) 
B6D2F  (7) 
B6D2F  (7) 
B6D2F  (5) 
B6D2F  (5) 
B6D2F  (5) 
B6D2F  (6) 
B6D2F  (4) 
B6D2F  (6) 
B6  5.0  -  -  2.3339 (2.1201-2.5691) 
B6  5.0  -  -  0.1770 (0.0548-0.5722) 
B6  5.0  -  +  0.0455 (0.0200-0.1036) | 
B6  5.0  EL-4  -  1.4967 (1.1558-1.9382) ! 
B6  5.0  EL-4  +  0.6989 (0.4899-0.9972)  0'! 
B6  5.0  L1210  -  0.1099 (0.0811-0.1489) 
B6  5.0  L1210  +  0.0322 (0.0247-0.0419)  ! 
B6  5.0  GL-I  -  0.0575 (0.0280-0.1174) 
B6  5.0  GL,!  +  0.0261  (0.0191-0.0357)  0 
B6  5.0  YAC,1  -  0.0860 (0.0282-0.2626) 
B6  5.0  YAC-I  +  0.0390 (0.0271-0.0562)  0 
* Irradiated inhibitor cells were given at the dose of l0  s per recipient  3 h before BMC grafting. For 
H-2 haplotype of tumor cells used, see Table II. 
* Prospective recipients  were given  100 #g of p-I:C i.p. 18 h before BMC grafting. 
| Statistically significant (P < 0.05) enhancement of graft rejection as compared with p-hC-untreated 
control. 
n  Statistically significant (P < 0.05) inhibition  of graft rejection  as compared with the recipients  not 
receiving tumor cells, with or without p-I:C treatment. 
Splenic Localization of  Inhibitory and Noninhibitory Lymphomas.  It was conceivable 
that the inhibitory  capacity of certain  lymphoma cells and its absence  in others 
depended  on  the  ability  to localize  in  the  host spleen,  rather  than  on  the  H-2 
haplotype. In addition, the reduced efficiency of inhibition in p-hC-treated hosts 
could reflect  a  lower efficiency of splenic  localization  of lymphoma cells in  the 
treated  than  in the  untreated  hosts.  To  test these possibilities,  the frequency of 
splenic  localization was studied  for selected  inhibitory and noninhibitory tumor 
cells  in  untreated  as  well  as  p-I:C-treated  F1  recipients.  Between  1  and  2%  of 
[125I]IUdR-labeled  tumor  cells  localized  in  the  spleen  1-2  h  after  injection, 
irrespective  of their  capacity to inhibit  hybrid  resistance  (Fig.  3).  Thus,  nonin- 
hibitory  L1210  (Fig.  3B)  and  YAC-1  and  GL-1  cells  (Fig.  3C)  localized  in  F1 
spleens  at  about  the  same  time  and  frequency as inhibitory  EL-4 or  L5MF-22 
cells  (Fig.  3A).  Pretreatment  of recipient  mice with  p-I:C did  not substantially 
alter  this  pattern,  although  there  was  a  trend  for  a  higher  initial  localization 
frequency and a  more rapid clearance of tumors from the spleens of treated than 
untreated  mice.  These  characteristics  were  remarkably  reproducible  in  inde- 
pendent  experiments  included,  or not included,  in Fig.  3.  It was also apparent, DALEY  AND  NAKAMURA  1141 
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FIGURE 3.  Splenic localization of lymphoma cells. One million [l*5I]IUdR-labeled lymphoma 
cells were injected intravenously  into irradiated B6D2FI or B10C3F~ mice with (closed symbols) 
or without (open symbols) p-I:C treatment 18 h earlier; the spleens were removed at intervals 
between 15 min and 24 h after injection and the 12sI activity in the spleens was measured. (A) 
EL-4 cells injected into B6D2F~ mice (O, O), and LSMF-22 cells injected into B10C3F] mice 
(A, A).  (B) LI210 cells  injected into B6D2FI mice (O, 0) or,  in another experiment, into 
B10C3F] mice (A, A). (C) YAC-I cells (O, 0) or, in a separate experiment, GL-1 cells (A, A) 
injected into B6D2F] mice. Each point represents the mean of three to five mice. 
not unexpectedly, that some minor differences exist among different tumor cells. 
For example, L1210  cells seemed to reach the spleen more slowly than EL-4, 
L5MF-22, YAC-1, or GL-1 cells, while both YAC-1 and GL-1 cells seemed to be 
cleared more rapidly from the spleen than either EL-4,  L5MF-22,  or  L1210 
cells. However, these characteristics did not obviously correlate with either the 
ability to inhibit parental H-2  b BMC rejection or susceptibility to NK-mediated 
cytolysis, at least within the 24 h observation period. 
Discussion 
The experiments described in this paper were undertaken to answer one of 
the most basic questions regarding the enigmatic phenomenon known as hybrid 
resistance, i.e., whether the immunogenetic specificity of resistance reflects the 
recognition specificity of putative effector cells. We addressed this issue through 
a new approach. The results show that inhibition in situ of hybrid resistance by 
irradiated tumor cells depends on (a) the strength of resistance, (b) the parental 
BMC graft size, (c) the inhibitor cell dose, (d) the time of inhibitor cell inoculation 
relative to bone marrow transplantation, and (e) the inhibitor cells' H-2 haplotype 
and homozygosity. It is unlikely that characteristics of tumor cells not associated 
with  the  H-2  haplotype,  such as  the cell  size,  splenic  localization  frequency, 
possible lymphokine or cytotoxin secretion, or the presence of alloreactive T 
lymphocytes accompanying in vivo-derived tumor cells that could be activated 
to  secrete lymphokines, played a  substantial  role.  Although not all  of the  16 1142  H-2/Hh-RESTRICTED  EFFECTORS OF  NATURAL RESISTANCE 
tumor lines used were tested for their effect on BMC transplantation in syngeneic 
donor/recipient combinations,  there was  no  evidence for nonspecific growth 
enhancement or suppression other than a slight depression in growth attributable 
to  initial  physical  crowding.  The  frequency of splenic  localization  was  also 
comparable so far as those cell lines tested were concerned. The H-2 haplotype 
and  homozygosity were consistently the most critical factors determining the 
inhibitory  capacity,  regardless  of whether  the  tumor  cells  in  question  were 
derived from in vivo or in vitro lines. The latter tumors were unlikely to contain 
immunocompetent cells,  since all  of them  had  been  passaged  in  vitro  for a 
number of years before being tested in this study. The tumor lines used in this 
study were chosen primarily for theivavailability in our laboratory, convenience, 
H-2 haplotype of the strain of origin, and NK susceptibility; no other tumor lines 
were  tested  or  excluded  for  unexpected  behavior.  In  addition,  the  genetic 
specificity of inhibition observed in this study has been confirmed and extended 
by using normal hemopoietic cells as inhibitors (Daley and Nakamura, manuscript 
in preparation). 
The inhibition of hybrid resistance by irradiated tumor cells could result from 
direct competition with parental BMC at the level of the effectors. Alternatively, 
inhibition could conceivably occur via determinant-specific regulatory cells mod- 
ulating  a  nonspecific effector mechanism.  For  example,  inhibitory  cells  may 
stimulate the reactive host cells to release nonspecific growth factors for trans- 
planted  hemopoietic  cells,  or  in  some  way  cause  suppression  of nonspecific 
rejection, cell-mediated or otherwise. The data provided in  the present study 
suggest, however, that the inhibition is unlikely to have a two-step mechanism. 
Firstly, inhibitory tumor cells had no effect on the growth of F~  BMC grafted 
into  syngeneic  F~  hosts.  The  release  of nonspecific  growth  factor(s)  or  the 
suppression of nonspecific effectors should have caused enhanced growth of F~ 
BMC  if either of these  mechanisms was  operative.  Secondly,  NK-susceptible 
tumor cells not bearing homozygous H-2D  b alleles had absolutely no detectable 
influence on the growth of parental BMC in  F~  hosts.  If nonspecific effectors 
with NK-iike reactivity played a role in hybrid resistance, one would expect NK- 
sensitive tumor cells to have at least some impact. It seems reasonable to conclude, 
therefore, that the inhibition of hybrid resistance observed in this study reflects 
specific competitive inhibition at the level of the effectors mediating the resist- 
ance. 
The present data have several interesting implications for the nature of the 
effector cells and the target antigens recognized in natural bemopoietic resist- 
ance. Most importantly, the results have confirmed the presence, in responder 
FI mice, of radioresistant effector cells that specifically recognize H-2Db/Hh-1 b 
homozygous BMC and promptly eliminate them or suppress their proliferation, 
as proposed in the original hypothesis (9). The effector cell activity could not be 
blocked by H-2Db/Hh-lb-negative tumor cells, including NK-susceptible YAC-1 
(H-2a),  RLc~-I (H-2a), or 416B that is heterozygous for H-2  b. Some alloreactive 
cytotoxic T  lymphocyte (CTL) clones have been shown to have a dual reactivity, 
one of which is MHC-restricted and the other, nonrestricted but directed to cell 
surface  structures  of  NK-sensitive  lymphomas  (39).  The  coexistence  of two 
independent recognition structures on some of these CTL clones has recently DALEY  AND  NAKAMURA  1143 
been demonstrated, but the binding of CTL to target cells through one type of 
receptor was found to block the binding through the other type of receptor (40). 
The  effectors  mediating  hybrid  resistance  did  not  exhibit  such  competitive 
binding, even under conditions that could have increased their binding capacity 
for NK-susceptible target cells, i.e., p-I:C pretreatment of the hosts. Therefore, 
barring the possibility that the effectors for resistance somehow manage to bind 
NK-sensitive  lymphoma cells without  impeding their  ability  to  bind  parental 
BMC, these effectors do not appear to have a dual recognition specificity. The 
relationship between the effectors of natural hemopoietic resistance and NK cells 
requires reassessment in the light of these data. Some of the shared properties 
of natural hemopoietic resistance and NK cell activity may only reflect a require- 
ment  for  the  same  accessory  functions.  It  is  possible  that  the  effectors  of 
hemopoietic resistance do belong to a  subset or a  differentiation stage of NK 
cells,  adding  another  dimension  to  the  known  heterogeneity of this  class  of 
effector cells. Alternatively, hemopoietic resistance may be mediated by a  new 
class of effector cells whose function depends in some way on interactions with 
NK cells. Further studies are needed to distinguish these possibilities and establish 
the identity of the resistance-mediating effectors. The augmentation of hybrid 
resistance by p-I:C is mediated by IFN, since semipurified IFN-~ is also effective 
and  anti-IFN-/3  antiserum  can  abrogate  the augmentation  (Cudkowicz et  al., 
unpublished  data).  Xenogeneic hemopoietic resistance has been  shown to  be 
potentiated by p-I:C (41). 
Our observations may seem at odds with the results of several recent studies. 
For instance, lysis of human BMC by autologous or allogeneic NK cells in vitro 
can be inhibited by NK-susceptible K562 erythroleukemic cells (21), and lysis of 
NK-sensitive  YAC-1  lymphoma targets  was  blocked  by  regenerating  murine 
hemopoietic cells syngeneic to  NK cells (22).  Assuming that the blocking was 
due to competitive binding with effector cells, the results would indicate that the 
same NK cells are reactive with normal hemopoietic cells as well as genetically 
unrelated lymphoma cells. In our view, the target structures recognized in these 
studies are unrelated to the determinants controlled by Hh genes or their human 
counterpart. The transferrin receptor has recently been suggested as a candidate 
for such  structures (42).  The  ability of a  cell  line  with  NK-like  reactivity to 
reconstitute resistance in vivo to allogeneic marrow grafts seems to contradict 
the present data, since these NK-like cells do not show immunogenetic specificity 
in vitro but appear to mediate specific allograft rejection in vivo (23). It remains 
to be seen, however, whether these NK-like cells directly function as effectors in 
vivo, or these cells secrete IFN-'r and activate or recruit endogenous effectors. 
Although the recognition specificity of effector cells mediating allogeneic marrow 
graft resistance has not been investigated in detail, our preliminary data suggest 
that these effectors, too, have immunogenetic specificity. In another study (43), 
lysis of EL-4 cells in vitro by NK-like splenic effectors of an F1 hybrid origin was 
inhibited  by  YAC-1  cells,  and  vice  versa.  However,  unlike  the  hemopoietic 
resistance in vivo (44), the in vitro activity was not dependent on bone marrow 
integrity (43, 45), suggesting that the in vitro cytotoxicity is mediated by effectors 
distinct from those analyzed in the present study. 
It  is  often  implicitly assumed  that  hybrid  resistance  to  parental  BMC  and 1144  H-2/Hh-RESTRICTED  EFFECTORS  OF  NATURAL  RESISTANCE 
lymphoma cells is  mediated by the same effectors, based on a  similar genetic 
control over resistance to these cells. It is probable that hybrid resistance against 
tumor cells involves a  variety of mechanisms (46-48).  In some cases, however, 
the assumption of identical effectors seems valid (9).  The present data indeed 
provide the first direct demonstration that the effectors mediating resistance to 
parental BMC are reactive with parental or other tumors of the H-2Db/Hh-1 b 
genotype. This observation may seem to contradict the reported failure to block 
hybrid resistance against a parental H-2  b lymphoma by inoculation of irradiated 
normal spleen cells from H-2  b mice (49).  The disagreement is probably more 
apparent than real, since several simple explanations are possible, such as higher 
density of target antigens on tumor cells than on normal splenocytes, relatively 
low frequencies of antigen-bearing cells among splenocytes of unmanipulated 
mice, or an insufficient inhibitor cell dose. 
The results of this study offer some initial insight on the nature of the cell 
surface antigens recognized by the effectors of hybrid resistance. The consistent 
failure to inhibit parental marrow graft rejection by four independent lines of 
H-2D b heterozygous cells indicates that the target antigens are either not ex- 
pressed on these cells or expressed at such low levels as to be undetectable by 
the assay. These data are in contrast with those obtained with F~ antiparental H- 
2 b CTL. In the latter, direct cytolysis is detectable only on H-2D  b homozygous 
target cells, but the lysis of such targets can be effectively  and specifically inhibited 
by H-2D  b heterozygous cells, including F1 hybrid cells syngeneic with the CTL 
(50). These data and the fact that monoclonal antibodies specific for D  b molecules 
block  the lysis of parental  target cells (Nakamura,  unpublished observations), 
indicate that  FI  antiparent CTL  recognize determinants controlled by class  I 
genes. The present results with H-2D  b heterozygous cells are consistent with the 
hypothesis that the effectors of resistance recognize Hh-1 b antigens expressed 
only on homozygous cells, rather than self antigens restricted by H-2D b.  How- 
ever, a  note of caution is  necessary for this  interpretation.  Since the present 
study  used  intact  F~  hosts,  the  effectors  were  surrounded  by  an  excess  of 
endogenous H-2 heterozygous cells. Should the endogenous cells express small 
amounts of target antigens, exogenous H-2 heterozygous inhibitors might not 
exert additional effects over preexisting partial autoinhibition. It is conceivable, 
therefore, that hybrid resistance represents a form ofautoreactivity that becomes 
detectable in intact F1 hybrid mice only when homozygous target cells are tested. 
Further comparisons between the recognition specificity of F1 antiparent CTL 
and that of the effectors mediating hybrid resistance will be useful in determining 
whether the putative  Hh-1 b antigen  is  distinct  from  the  known  class  I  gene 
products.  Discordant genetic patterns  between the  two  F~  hybrid antiparent 
reactivities have already been pointed out (51).  In a  series of ongoing studies, 
normal hemopoietic cells from a panel of inbred strains of mice have been used 
as inhibitors for hybrid resistance against parental H-2  b BMC. The results so far 
indicate that the effector specificity is consistent with the known strain distribu- 
tion and properties of Hh-1 alleles and not with class I H-2 specificities defined 
by serological reagents, allogeneic anti-H-2D  b,  or F1  antiparental H-2D  b CTL 
(Daley and Nakamura, manuscript in preparation). Analyses of effectors respon- 
sible for hybrid resistance against parental BMC  from various H-2  d strains of DALEY  AND  NAKAMURA  1145 
mice are also in progress. Since the Hh loci defined by H-2  d strains of mice have 
been identified either at some distance from the D end of the H-2 complex or 
not linked to the H-2 (18), such studies should be particularly informative. 
Summary 
The natural resistance of Fa hybrid mice against parental bone marrow grafts 
is  thought  to  be mediated  by natural  killer  (NK)-like  effector cells.  However, 
unlike  the  NK cell  activity against  a  wide range  of tumors  and  normal  cells, 
hybrid resistance is characterized by the immunogenetic specificity controlled by 
a set of unique noncodominant genes denoted as Hh. Two alternative hypotheses 
can account for the specificity. Thus,  the specificity may reflect either  the  Hh 
restriction  of effectors or the Hh gene control of mechanisms regulating  non- 
Hh-restricted effector activity. In this study, therefore, we tested the recognition 
specificity of putative effectors mediating hybrid resistance in lethally irradiated 
H-2  b/d and  H-2  b/k  F~  hybrid  mice  to  the  engraftment  of parental  H-2  b bone 
marrow.  As  a  direct  means  of defining  the  effector  specificity,  rejection  of 
parental  bone marrow grafts was subjected to competitive inhibition  in situ by 
irradiated  tumor  cells.  Of the  16  independent  lines  of lymphoma  and  other 
hemopoietic tumor cells tested,  the ability to inhibit  hybrid resistance  was the 
exclusive property of all tumors derived from mice homozygous for the H-2D  b 
region, regardless of whether the tumor cells were susceptible or resistant to NK 
cell-mediated  cytotoxicity in  vitro.  Four cell lines  heterozygous for the  H-2D  b 
were noninhibitory,  including one that is susceptible to natural killing.  Pretreat- 
ment of the FI hosts with an interferon  inducer augmented the resistance with 
no alteration  in the recognition  specificity of effector cells. Therefore,  natural 
resistance  to  parental  H-2  b  bone  marrow  grafts  was  mediated  by  effectors 
restricted by the  H-2Db/Hh-1 b gene(s), and not by the nonrestricted  NK cells 
detectable in conventional in vitro assays. 
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